[
  {
    "QuestionID": "Q1",
    "Question": "What is the type of XL-228?",
    "Answer": "inhibitor",
    "QuestionType": "cell selection",
    "TableName": "table-1.csv",
    "Explanation": "The answer can be found in the 'Type' column of the table, where XL-228 is listed as an inhibitor.",
    "GT": "inhibitor"
  },
  {
    "QuestionID": "Q2",
    "Question": "What is the clinical indication for which dasatinib alleviates symptoms?",
    "Answer": "RA in mouse models",
    "QuestionType": "cell selection",
    "TableName": "table-1.csv",
    "Explanation": "The answer can be found in the 'Clinical indication' and 'Application in immune-mediated diseases' columns of the table, where dasatinib is listed as alleviating symptoms of RA in mouse models.",
    "GT": "cancer"
  },
  {
    "QuestionID": "Q3",
    "Question": "What is the phase status of tosedostat for ERAP2?",
    "Answer": "-",
    "QuestionType": "cell selection",
    "TableName": "table-1.csv",
    "Explanation": "The answer can be found in the 'Phase' column of the table, where tosedostat for ERAP2 is listed as having no phase status.",
    "GT": "-"
  },
  {
    "QuestionID": "Q4",
    "Question": "What is the type of abatacept?",
    "Answer": "CTLA4-mimicking",
    "QuestionType": "cell selection",
    "TableName": "table-1.csv",
    "Explanation": "The answer can be found in the 'Type' column of the table, where abatacept is listed as a CTLA4-mimicking agent.",
    "GT": "CTLA4-mimicking"
  },
  {
    "QuestionID": "Q5",
    "Question": "Which drug is listed as having a predisposing effect for MS?",
    "Answer": "firategrast",
    "QuestionType": "cell selection",
    "TableName": "table-1.csv",
    "Explanation": "The answer can be found in the 'Application in immune-mediated diseases' and 'Phase' columns of the table, where firategrast is listed as having a predisposing effect for MS and is in phase II completed.",
    "GT": "firategrast"
  }
]